ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.17
0.50%
US Tech 100
20,092.80
-0.17%
S&P 500
5,906.88
-0.17%
US Dollar vs CAD
1.39573
-0.09%
Bitcoin
96,884.73
2.68%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Hemogenyx Pharmaceuticals Plc (HEMO)

  7. Hemogenyx Pharmaceuticals Plc (HEMO) News

HEMO

Hemogenyx Pharmaceuticals (HEMO)

Hemogenyx Pharmaceuticals Plc
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:HEMO
DateTimeSourceHeadlineSymbolCompany
11/11/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Institutional InvestmentLSE:HEMOHemogenyx Pharmaceuticals Plc
10/30/20246:09AMAlliance NewsAlliance NewsIN BRIEF: Hemogenyx to launch myeloid leukemia treatment phase 1 trialLSE:HEMOHemogenyx Pharmaceuticals Plc
10/30/20242:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Schedule for Phase I Clinical Trial OpeningLSE:HEMOHemogenyx Pharmaceuticals Plc
10/02/20245:19AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Strategic Investment from Prevail Partners, LLCLSE:HEMOHemogenyx Pharmaceuticals Plc
09/27/202412:25PMAlliance NewsAlliance NewsHemogenyx Pharmaceuticals loss narrows amid reduced expensesLSE:HEMOHemogenyx Pharmaceuticals Plc
09/27/20249:55AMAlliance NewsAlliance NewsEARNINGS: Clean Power Hydrogen loss widens; Invinity loss narrowsLSE:HEMOHemogenyx Pharmaceuticals Plc
09/27/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Half-year ReportLSE:HEMOHemogenyx Pharmaceuticals Plc
09/09/20244:03PMAlliance NewsAlliance NewsTRADING UPDATES: Light Science Technologies wins two new contractsLSE:HEMOHemogenyx Pharmaceuticals Plc
09/09/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC FLT3 Assay Ready for Phase I Trials at MD AndersonLSE:HEMOHemogenyx Pharmaceuticals Plc
09/02/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC CDX Development UpdateLSE:HEMOHemogenyx Pharmaceuticals Plc
08/28/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Presentation at CBD S&T ConferenceLSE:HEMOHemogenyx Pharmaceuticals Plc
07/29/20241:00AMRNS Non-RegulatoryHemogenyx Pharmaceuticals PLC Macrophage-Directed Therapies Summit PresentationLSE:HEMOHemogenyx Pharmaceuticals Plc
06/27/202410:39AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Result of Annual General MeetingLSE:HEMOHemogenyx Pharmaceuticals Plc
06/17/20241:55PMAlliance NewsAlliance NewsIN BRIEF: Hemogenyx Pharmaceuticals updates on leukemia treatmentLSE:HEMOHemogenyx Pharmaceuticals Plc
06/17/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Operations UpdateLSE:HEMOHemogenyx Pharmaceuticals Plc
06/03/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Posting of Annual Report & Notice of AGMLSE:HEMOHemogenyx Pharmaceuticals Plc
04/25/20246:19AMAlliance NewsAlliance NewsEARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payoutLSE:HEMOHemogenyx Pharmaceuticals Plc
04/25/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Final ResultsLSE:HEMOHemogenyx Pharmaceuticals Plc
03/28/20242:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Total Voting RightsLSE:HEMOHemogenyx Pharmaceuticals Plc
02/29/20248:04AMAlliance NewsAlliance NewsHemogenyx Pharmaceuticals raises money for leukaemia treatmentLSE:HEMOHemogenyx Pharmaceuticals Plc
02/29/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Placing to Raise US$4.2 millionLSE:HEMOHemogenyx Pharmaceuticals Plc
02/16/20245:27AMAlliance NewsAlliance NewsHemogenyx shares rise on potential for CBR to treat brain diseasesLSE:HEMOHemogenyx Pharmaceuticals Plc
02/16/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC CBR Brain DeliveryLSE:HEMOHemogenyx Pharmaceuticals Plc
02/14/20244:14AMAlliance NewsAlliance NewsHemogenyx says CBR can be used intranasally to treat viral infectionsLSE:HEMOHemogenyx Pharmaceuticals Plc
02/14/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC CBR Intranasal DeliveryLSE:HEMOHemogenyx Pharmaceuticals Plc
02/09/20244:00AMAlliance NewsAlliance NewsIN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial holdLSE:HEMOHemogenyx Pharmaceuticals Plc
02/09/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC FDA Consents to Phase I Trials of HEMO-CAR-TLSE:HEMOHemogenyx Pharmaceuticals Plc
02/02/20244:44AMAlliance NewsAlliance NewsIN BRIEF: Hemogenyx hails US patent application progressLSE:HEMOHemogenyx Pharmaceuticals Plc
02/02/20241:00AMRNS Regulatory NewsHemogenyx Pharmaceuticals PLC Approval and Issuance of U.S. Conditioning PatentLSE:HEMOHemogenyx Pharmaceuticals Plc
01/16/20245:13AMAlliance NewsAlliance NewsHemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDALSE:HEMOHemogenyx Pharmaceuticals Plc
 Showing the most relevant articles for your search:LSE:HEMO

Your Recent History

NASDAQ
NVDA
NVIDIA
NASDAQ
QUBT
Quantum Computing
USOTC
SINC
Sincerity Applied Materi... (PK)
COIN
BTCUSD
Bitcoin
USOTC
NSAV
Net Savings Link (PK)
USOTC
APRU
Apple Rush (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
MGON
Megola (PK)
USOTC
VDRM
ViaDerma (PK)
USOTC
TGLO
TheGlobe com (PK)
NASDAQ
NB
NioCorp Developments
USOTC
AHRO
Authentic (PK)
COIN
SHIBUSD
SHIBA INU
USOTC
BCAP
Baron Capital Enterprise (CE)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
HHSE
Hannover House (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved